![]() |
|
|
Vol. 296, Issue 3, 806-810, March 2001
Vanderbilt University Medical Center, Departments of Internal
Medicine and Pharmacology, Divisions of Clinical Pharmacology and
Cardiovascular Medicine, Nashville, Tennessee (M.E.A., T.Y., D.M.R.);
and Department of Cardiology, Rabin Medical Center, Belinson Campus and
Sackler School of Medicine, Tel Aviv University, Israel (A.M.)
Quinolones are clinically important antibiotic drugs. One quinolone
antibiotic, sparfloxacin (SPX), has been recently reported to increase
the QT interval, and another quinolone, grepafloxacin (GRX), was
withdrawn because it induced torsade de pointes (TdP), a polymorphic
ventricular tachycardia (VT) linked to excessive QT interval
prolongation. To determine whether SPX, GRX, and other recently
developed quinolones, gatifloxacin (GAT) and moxifloxacin (MOX), have
similar, potentially deleterious, properties we compared these agents
in two ways. First, we measured their relative antagonist potency
against the rapid component of the delayed rectifier K+
current (IKr), and second we determined the QT interval
prolongation and inducibility of VT and TdP using a well established in
vivo rabbit arrhythmia model. All of these agents are IKr
antagonists with the following IC50 values (mean ± S.E.) for IKr block: SPX, 0.23 ± 0.07 µM; MOX,
0.75 ± 0.31 µM; GAT, 26.5 ± 13.4 µM; and GRX, 27.2 ± 11.6 µM. All agents also increased the maximum QT interval
(mean ± S.E.) from baseline (241 ± 10 ms): SPX, 370 ± 30 ms; MOX, 270 ± 30 ms; GRX, 280 ± 25 ms; and GAT,
255 ± 23 ms. No agents caused TdP during a standard 30-min
observation period, but SPX-treated animals developed nonsustained VT
(three of six) and TdP (one of six) during an extended 60-min
observation period. These findings show that IKr block may
be a common feature of many quinolone antibiotics, and that the
proarrhythmic consequences vary according to IKr antagonist
potency, but are also influenced by additional, unidentified factors.
This article has been cited by other articles:
![]() |
T. Wisialowski, K. Crimin, J. Engtrakul, J. O'Donnell, B. Fermini, and A. A. Fossa Differentiation of Arrhythmia Risk of the Antibacterials Moxifloxacin, Erythromycin, and Telithromycin Based on Analysis of Monophasic Action Potential Duration Alternans and Cardiac Instability J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 352 - 359. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. A. Kuryshev, E. Ficker, L. Wang, P. Hawryluk, A. T. Dennis, B. A. Wible, A. M. Brown, J. Kang, X.-L. Chen, K. Sawamura, et al. Pentamidine-Induced Long QT Syndrome and Block of hERG Trafficking J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 316 - 323. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Smith and B. M. Lomaestro What Role do Fluoroquinolone Antimicrobial Agents Play in Cardiac Dysfunction and Altered Glycemic Control? Journal of Pharmacy Practice, October 1, 2003; 16(5): 349 - 360. [Abstract] [PDF] |
||||
![]() |
S. M. Al-Khatib, N. M. A. LaPointe, J. M. Kramer, and R. M. Califf What Clinicians Should Know About the QT Interval JAMA, April 23, 2003; 289(16): 2120 - 2127. [Abstract] [Full Text] [PDF] |
||||